AbbVie turns its back on Harpoon’s BCMA-targeting multiple myeloma drug
AbbVie is walking away from an exclusive option for Harpoon’s BCMA-targeting T cell engager for multiple myeloma, leaving the California company to advance the asset alone.
The agreement will end on Oct. 12, after which the drug, HPN217, will be fully owned by Harpoon. The biotech said it would complete an ongoing Phase I trial of the asset in relapsed or refractory multiple myeloma with interim data to be presented at the annual International Myeloma Society meeting on Sept. 28, with an eye to supporting further development.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.